| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.8 |